Medically reviewed by Dr Sin Yong · Last reviewed · 13 min read · Doctor-performed, never delegated · Jump to questions
Dr Sin Yong · MBBS (NUS) · MRCS (Edin) · MSc Aesthetic Medicine with Distinction (Queen Mary, London) · MSc Practical Dermatology (Cardiff) · International KOL
Wegovy is the once-weekly semaglutide injection registered for weight management — the medicine most people mean when they say “the weight loss jab”. It is also a prescription-only medicine in Singapore: you qualify for it through medical assessment, you are titrated and monitored through it, and the programme plans for the day you stop. This page explains it honestly; suitability is a consultation decision.
Wegovy is once-weekly semaglutide 2.4 mg, a GLP-1 receptor agonist registered for chronic weight management. In Singapore it is a prescription-only medicine: eligibility is decided by medical assessment, including BMI and weight-related conditions, followed by supervised dose titration, side-effect monitoring, muscle preservation and a plan for stopping.
Wegovy is semaglutide at 2.4 mg — a GLP-1 receptor agonist formulated and registered specifically for chronic weight management, injected once weekly with a fine pre-filled pen. It amplifies the body’s own satiety signalling: appetite quietens, portions shrink without white-knuckle willpower, and the constant food-noise many patients describe goes silent. In the landmark STEP 1 trial (New England Journal of Medicine, 2021), adults on semaglutide 2.4 mg achieved substantially greater weight loss than lifestyle change alone — the result that changed obesity medicine.
In Singapore, Wegovy is an HSA-regulated prescription-only medicine with defined eligibility: BMI thresholds, adjusted when weight-related conditions such as pre-diabetes, hypertension or sleep apnoea are present. It cannot be bought on request — and any online seller offering it without a doctor’s assessment is the red flag, not the shortcut. Here the sequence is medical: history, examination and metabolic screening; an eligibility decision; then a supervised programme — stepwise dose titration, side-effect management, muscle preservation and an exit strategy. The full programme is described on the medical weight loss page.
Semaglutide mimics GLP-1, a gut hormone released after eating. It signals fullness to the brain, slows stomach emptying and steadies insulin response — so hunger arrives later, satisfaction arrives earlier, and total intake falls naturally. Dosing starts low (0.25 mg) and climbs stepwise over months to the 2.4 mg maintenance dose; that slow climb is deliberate, because it is how the early nausea and reflux most people fear are kept manageable.
The honest limits: weight lost on Wegovy includes muscle unless protein intake and resistance training are planned — one reason unsupervised use ages people. Rapid loss deflates structural facial fat (the pattern nicknamed “Ozempic face” — semaglutide is the same molecule). And appetite physiology returns when the injections stop, which is why the maintenance plan is designed on day one, not improvised at the end. These are the differences between being sold a pen and being taken through a programme.
Wegovy is indicated at defined BMI thresholds, lower when weight-related conditions are present. Assessment decides — and if you do not qualify, you are told why, with honest alternatives.
From 0.25 mg to 2.4 mg over months, adjusted to your tolerance. Most side effects are early, gastro-intestinal and manageable when the climb is unhurried.
Same molecule, different registrations: Ozempic is the diabetes formulation; Wegovy is registered for weight management with its own dosing. Which — if either — fits you is a prescribing decision, not a branding one.
Protein targets, resistance training and body-composition tracking are built in, so what you lose is fat rather than the muscle that keeps you metabolically healthy.
Rapid loss empties facial fat compartments. Pacing reduces it; where it has happened, restoration is its own discipline — see Ozempic face treatment.
Appetite returns when the medicine stops. The maintenance plan — habits, monitoring, and any body or facial contour work at stable weight — is designed before the last dose, not after regain.
“Wegovy is not a purchase. It is a medical treatment you qualify for, are guided through, and are planned out of.”Dr Sin Yong
References: Once-Weekly Semaglutide in Adults with Overweight or Obesity — STEP 1 Trial (Wilding et al., NEJM 2021) · Rising Public Interest in Weight Loss Medications and Their Aesthetic Sequelae (McCarthy et al., 2026)
History, examination, metabolic screening and body composition. Eligibility for Wegovy is decided against established criteria — with alternatives discussed honestly if it is not appropriate for you.
If indicated, you start at 0.25 mg weekly with clear guidance on injection technique, what to expect, and what should prompt a call to the clinic.
“A weight-loss medicine is a medical treatment with its own monitoring, not a cosmetic add-on.”
Dr Sin YongOn GLP-1 medicines
Doses step up on schedule as tolerated. Regular reviews track weight, body composition, side effects, nutrition and training — the programme adjusts to you.
At goal, the maintenance strategy takes over — and any facial or body contour planning happens at stable weight, in the right order.
People who want a quick cosmetic change below the eligibility criteria, or who will not attend titration reviews, tend to respond poorly, and Wegovy is the wrong tool for them.
Nausea, reflux and constipation are common early and usually settle when the dose is raised gradually. Reduced appetite is the intended effect, but it can reduce protein intake, and some of the weight lost can be muscle without planned training. Rapid loss can deflate facial fat, the pattern nicknamed Ozempic face. Gallbladder disease and pancreatitis are recognised, less common complications. Injection-site redness or bruising can occur. Buying Wegovy online without assessment adds risks of wrong dose, contamination and missed interactions, which is why it is prescribed and monitored by a doctor.
The fee depends on the dose stage reached during titration, how often reviews and body-composition checks are needed, and whether nutrition guidance or facial and body contour planning is added to your plan. Wegovy is prescription-only, so it is prescribed only if indicated. A written quote is given at consultation, after history, examination and metabolic screening. The consultation also decides whether Wegovy is advised at all; if you do not qualify, you are told why and offered alternatives.
How quotes work at this practice: how we quote.
It is a prescription-only medicine that needs an eligibility assessment, supervised titration and monitoring.
They contain the same molecule, semaglutide, with different registrations and dosing, and which fits is a prescribing decision.
Yes — Wegovy (semaglutide 2.4 mg) is available in Singapore as a prescription-only medicine. It is prescribed after a medical assessment confirms you meet the eligibility criteria, and used under doctor supervision with scheduled reviews.
They contain the same molecule, semaglutide. Ozempic is registered for type 2 diabetes; Wegovy is the higher-dose formulation registered specifically for weight management with its own titration schedule. Which is appropriate — if either — is a prescribing decision made on your medical picture.
Semaglutide mimics the gut hormone GLP-1: it signals fullness to the brain, slows stomach emptying and steadies insulin response. Appetite falls naturally, portions shrink, and the constant urge to snack quietens — which is why it outperforms willpower-based dieting in trials.
Responses vary genuinely between individuals, and Singapore's advertising rules rightly prevent outcome promises. What can be said: the randomised STEP trials showed substantially greater loss with semaglutide 2.4 mg than lifestyle change alone, and your own trajectory is reviewed against your plan at each visit.
Eligibility follows BMI thresholds, adjusted downward when weight-related conditions such as pre-diabetes, hypertension or obstructive sleep apnoea are present. It is confirmed at medical assessment — pursuing it below criteria, or from unregulated online sellers, carries real risk.
Nausea, reflux and constipation are common early and usually settle with slow titration. Gallbladder disease and pancreatitis are recognised, less common risks; muscle loss is a practical concern the programme actively manages. Your personal risk picture is discussed before any prescription.
The pen uses a very fine needle into the skin of the abdomen, thigh or arm; most patients describe it as barely felt. You are taught the technique at the first visit and inject at home on the same day each week.
Rapid weight loss deflates the structural fat that supports the face — the pattern nicknamed “Ozempic face”, which applies to semaglutide by any brand name. Slower, supervised loss with muscle preservation reduces it, and a dedicated restoration pathway exists if it has already happened.
Appetite signalling returns when the medication stops, and regain is common without a maintenance plan — that is physiology, not weakness. This is why the exit strategy is designed at the start of the programme, not at the end.
Not legally in Singapore. Sellers offering it without a doctor's assessment are the warning sign — counterfeit and mishandled GLP-1 products are well documented, and an unscreened prescription skips the safety checks that make this medicine appropriate.
They work on different receptor combinations (Wegovy on GLP-1; Mounjaro on GLP-1 and GIP), and both have published trial support. “Better” is individual — history, tolerability, response and availability all matter, and that is what the assessment weighs.
Prescription medicine pricing is not advertised. Cost depends on dose stage and programme structure, and is set out transparently at consultation before you decide anything.
It can be worthwhile for adults who meet eligibility criteria, accept supervised titration and reviews, and want a plan for maintenance. It is not suited to those who are pregnant, have certain thyroid or pancreatic histories, or want a quick cosmetic change below the criteria. Medical assessment decides which group you are in.
Wegovy acts on appetite only while it is being taken, because appetite physiology returns once the injections stop. How long someone remains on it depends on response, tolerance, health goals and the maintenance plan. No duration is promised; the plan for stopping is set at consultation and revisited at each review.
Nausea, reflux and constipation are common early. Muscle can be lost alongside fat unless protein and resistance training are planned, and rapid weight loss can thin the face. Gallbladder disease and pancreatitis are recognised, less common risks. Appetite returns after stopping, and treatment needs ongoing supervision and cost.
Question not answered here? Ask on WhatsApp, use the enquiry form, or browse 100 questions patients ask.
Medically reviewed by Dr Sin Yong, MBBS (NUS), MRCS (Edinburgh) · Last updated 7 October 2026 · Editorial policy
Start with a message, not an appointment. Tell us your goal and rough history on WhatsApp, and you will get a straightforward reply about whether a Wegovy assessment makes sense for you.
Replies within clinic hours: Mon–Fri 10am–8pm, Sat 11am–3pm · How consultations work · Prefer not to use WhatsApp? · Treatment finder
WhatsApp +65 8023 7170This page is general information, not a diagnosis. Suitability for any treatment is decided at an in-person medical assessment.